Eli Lilly and Company $LLY Stock Bought by Forbes J M & Co. LLP

Key Points

• Forbes J M & Co. LLP increased its Eli Lilly stake by 26.2% in the third quarter, bringing its holdings to 14,886 shares valued at approximately $17.2 million. Institutional investors and hedge funds collectively own 82.53% of LLY.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $1,313.43; 24 analysts rate the stock Buy, while three rate it Hold and one rates it Sell.
• Eli Lilly reported strong quarterly results, including $8.38 in earnings per share and $22.97 billion in revenue, up 47.7% year over year. However, recent insider selling and the stock’s premium valuation could create short-term risks despite growth prospects from its obesity-drug pipeline.

Forbes J M & Co. LLP grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 26.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,886 shares of the company's stock after purchasing an additional 3,091 shares during the quarter. Eli Lilly and Company comprises approximately 1.2% of Forbes J M & Co. LLP's portfolio, making the stock its 23rd largest holding. Forbes J M & Co. LLP's holdings in Eli Lilly and Company were worth $17,224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Bank of America Corp DE purchased a new position in Eli Lilly and Company during the second quarter worth about $13,522,666,000. Jupiter Topco LLC acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $4,667,180,000. Fifth Third Bancorp increased its position in shares of Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Eli Lilly and Company by 353.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company's stock valued at $1,425,859,000 after buying an additional 1,208,510 shares during the last quarter. Finally, Corient Private Wealth LP purchased a new position in Eli Lilly and Company during the second quarter worth about $764,116,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on LLY shares. Weiss Ratings raised Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an "overweight" rating in a report on Monday, September 28th. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a "buy" rating in a report on Thursday, September 17th. Finally, TD Cowen restated a "buy" rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $1,313.43.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,258.04 on Monday. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65. The stock's 50-day moving average price is $1,180.08 and its 200 day moving average price is $1,109.55. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.18 trillion, a PE ratio of 42.22, a price-to-earnings-growth ratio of 1.67 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same period last year, the business posted $6.31 EPS. The company's revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 33.56 EPS for the current year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: European backing for Foundayo: The European Medicines Agency’s advisory committee issued a positive recommendation for Foundayo (orforglipron), Lilly’s once-daily oral GLP-1 treatment for obesity and type 2 diabetes. Final approval from the European Commission is still required, but the decision supports Lilly’s strategy to expand beyond injectable drugs and could broaden access to the rapidly growing weight-loss market. Eli Lilly’s GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
• Positive Sentiment: Additional obesity drugs could extend growth: Analysts and market commentators highlighted Foundayo, investigational retatrutide and other newer medicines as potential drivers of Lilly’s next growth phase, reducing dependence on Zepbound. Retatrutide remains in development, so its commercial contribution depends on clinical results and future regulatory approval. Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly’s Next Leg Higher
• Positive Sentiment: Pipeline diversification is improving: New Omvoh analyses showed meaningful one-year corticosteroid-free disease control in ulcerative colitis and Crohn’s disease, including patients who had failed prior biologics. Lilly also announced oncology research collaborations, adding potential long-term pipeline value beyond its GLP-1 franchise. New Omvoh Composite Outcomes Data
• Neutral Sentiment: Valuation remains a risk: Lilly’s exceptional obesity-driven growth and strong recent performance have pushed investor expectations high. Articles questioned whether future cash-flow growth is sufficient to justify the stock’s premium valuation, increasing the possibility of volatility if results or guidance disappoint. Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
• Negative Sentiment: Large shareholder sale adds a technical overhang: The Lilly Foundation is selling approximately 300,000 shares valued near $347 million. Reports indicate the transaction is not tied to concerns about Lilly’s business outlook, but a sizable sale can still raise short-term supply and sentiment concerns. Eli Lilly’s Biggest Shareholder Is Selling $347 Million of Stock

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.